MultiplexDX continues its streak of award-winning in 2018, having already been labeled “the emerging biotechnology star of Central Europe.” Last week, the company won 3 CESAwards: Best Social Impact of the Year, Best Biotech Startup, and Founder of the Year (Pavol Cekan). The Central European Startup Awards—the Central and Eastern Europe division of the Global Startup Awards—aims to find, highlight, and showcase the future-shapers of Poland, Czechia, Slovakia, Hungary, Austria, Serbia, Slovenia, Croatia, Romania, and Bulgaria. This year, the best and the most innovative startups competed in 14 categories, as well as investors, co-working centers and incubators. MultiplexDX was definitely one of the favorites.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“Getting three awards at once was a great surprise for us! On behalf of the MultiplexDX team, I'd like to thank CESAwards' experts for such a glowing evaluation of our project. We are very excited to represent Slovakia in the regional round in Warsaw, and to tell the world more about our innovations in cancer diagnostics!”
The CESAwards regional round will take place in Warsaw on the 24th of October, 2018. There, national winners from 10 Central and Eastern European countries will compete for the final prize.
Central European Startup (CES) Awards is the biggest no-pitch, no-conference startup festival in the Central European region. It is a part of the Global Startup Awards, providing an annual spotlight to those who dare to dream big and shape our future. It brings together the best ideas and minds from 45 countries worldwide to celebrate the entrepreneurial spirit and the unique ecosystems of startups.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.